Mandate

Vinge advises Nanoform in connection with its capital raising and listing on Nasdaq First North Premier Growth markets Finland and Sweden

Vinge has advised Nanoform Finland Plc (“Nanoform”) in connection with its capital raising and listing on Nasdaq First North Premier Growth markets Finland and Sweden.

The prospectus was published on 25 May 2020 and the trading on Nasdaq First North Premier began on 4 June 2020. The total value of the offering amounted to approximately EUR 88 million, assuming that the over allotment option is fully exercised.
 
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services.
 
Vinge’s team primarily consisted of Dain Hård Nevonen, Rikard Lindahl, Hampus Olsson and Julia Hirschberg. 
 

Related

Vinge advised Dr Schär

Vinge advised Dr Schär in the acquisition of Semper AB:s glutenfree business Dr. Schär, an Italian based company, is a developer of product for special nutritional needs.
February 29, 2024

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue
February 29, 2024

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").
February 29, 2024